Table 1.
Subject characteristics.
| Subject no. | Age(years) | Sex | Body weight(kg) | FVC(% predicted) | FEV1 (% predicted) | FEV1/FVC(%) | PC20-MCh(mg ml−1) | Treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | 39 | F | 78 | 108.5 | 86.9 | 72.1 | 0.13 | Sa, Be (800) |
| 2 | 41 | F | 55 | 94.8 | 71.6 | 72.6 | 2.37 | Sa, Be (800) |
| 3 | 22 | M | 67 | 119.4 | 73.9 | 60.9 | 0.52 | Sa, Be (200) |
| 4 | 62 | M | 62 | 112.3 | 90.8 | 65.0 | 3.55 | Sa, Be (200) |
| 5 | 53 | F | 76 | 80.5 | 77.0 | 74.2 | 0.40 | Sa |
| 6 | 63 | F | 56 | 100.3 | 78.1 | 81.7 | 0.14 | Sa, Be (200) |
| 7 | 39 | M | 62 | 126.4 | 115.1 | 82.5 | 0.84 | Sa |
| 8 | 47 | M | 60 | 114.6 | 61.8 | 7.15 | 81.0 | Sa, Be (200) |
| 9 | 33 | M | 76 | 112.1 | 84.1 | 70.5 | 1.58 | Sa |
| 10 | 40 | M | 60 | 107.2 | 83.5 | 66.7 | 0.14 | Sa, Be (400) |
| 11 | 29 | M | 63 | 124.2 | 88.6 | 65.7 | 0.13 | Sa, Be (200) |
| 12 | 21 | M | 66 | 101.9 | 79.8 | 73.4 | 0.86 | Sa |
| Mean ± s.e.m. | 41 ± 4 | 65 ± 2 | 108.5 ± 3.7 | 84.2 ± 3.3 | 70.6 ± 2.0 | 0.638* ± 0.175** |
Be (µg), Beclomethasone dipropionate via metered dose inhaler (daily inhaled dose); Sa, salbutamol via metered dose inhaler on demand; PC20-MCh, methacholine concentration producing a 20% fall in FEV1.
*
Geometric mean
**
geometric standard error of the mean.